Michael J. Mitten

11.8k citations

27 papers · 2.8k indexed · 1 hit paper · h-index 16

Impact in

Genetics top 2%
- Chronic Lymphocytic Leukemia Research
Hematology top 2%
- Multiple Myeloma Research and Treatments

Papers in

Microbiology 3
- Bacterial Infections and Vaccines 3
Hematology 5
- Multiple Myeloma Research and Treatments 4

Co-authors: Saul H. Rosenberg Steven W. Elmore Christin Tse Stephen W. Fesik Stephen K. Tahir Alexander R. Shoemaker Kennan C. Marsh Xiao Yu
Journals: Molecular Cancer Therapeutics (6 papers)Antimicrobial Agents and Chemotherapy (5 papers)Bioorganic & Medicinal Chemistry Letters (2 papers)Journal of Medicinal Chemistry (2 papers)Blood (2 papers)
Partner nations: United States Australia Portugal

In The Last Decade

Michael J. Mitten

27 papers receiving 2.7k citations

Hit Papers

align trajectories log scale

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor 2008 · 1.5k citations

Peers

Countries citing papers authored by Michael J. Mitten

Since Specialization

Citations

This map shows the geographic impact of Michael J. Mitten's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael J. Mitten with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael J. Mitten more than expected).

Fields of papers citing papers by Michael J. Mitten

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael J. Mitten. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael J. Mitten. The network helps show where Michael J. Mitten may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Michael J. Mitten, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael J. Mitten Line = papers co-authored together Michael J. Mitten links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR Journal of Neuro-Oncology ·Kedar S. Vaidya, Michael J. Mitten, M. Idzik, Anatol Oleksijew, Cory Alvey, Hugh D. Falls, Икромова Феруза, Joann P. Palma, Peter Ansell, Andrew C. Phillips, Edward B. Reilly, Mark G. Anderson, Erwin R. Boghaert	2021	9
2	Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody–Drug Conjugate Molecular Cancer Therapeutics ·Mark G. Anderson, Hugh D. Falls, Michael J. Mitten, Anatol Oleksijew, Kedar S. Vaidya, Erwin R. Boghaert, Wenqing Gao, Joann P. Palma, Diana Cao, S. Sukkhasena, Thomas John, Hui Gan, Andrew M. Scott, Edward B. Reilly	2020	30
3	Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors Molecular Cancer Therapeutics ·Lloyd T. Lam, Xiaoyu Lin, Emily J. Faivre, Ziping Yang, Xiaoli Huang, Denise M. Wilcox, Richard J. Bellin, Sha Jin, Stephen K. Tahir, Michael J. Mitten, Yury S. Ershov, Anahita Bhathena, Warren M. Kati, Daniel H. Albert, Yu Shen, Tamar Uziel	2017	55
4	The Volume of Three-Dimensional Cultures of Cancer Cells In Vitro Influences Transcriptional Profile Differences and Similarities with Monolayer Cultures and Xenografted Tumors Neoplasia ·Erwin R. Boghaert, Xin Lü, Paul Hessler, Thomas McGonigal, Anatol Oleksijew, Michael J. Mitten, Feng Bingmei, Jonathan A. Hickson, Vítor Espirito Santo, Catarina Brito, Tamar Uziel, Kedar S. Vaidya	2017	25
5	A “Prozone-Like” Effect Influences the Efficacy of the Monoclonal Antibody ABT-700 against the Hepatocyte Growth Factor Receptor Pharmacology ·Kedar S. Vaidya, Anatol Oleksijew, Lora A. Tucker, William N. Pappano, Mark G. Anderson, Christine Grinnell, Qian Zhang, Vázquez Osorio, Michael J. Mitten, Икромова Феруза, Joann P. Palma, Jieyi Wang, Edward B. Reilly, Erwin R. Boghaert	2017	4
6	ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope Molecular Cancer Therapeutics ·Andrew C. Phillips, Erwin R. Boghaert, Kedar S. Vaidya, Michael J. Mitten, Suzanne M. Norvell, Hugh D. Falls, Peter J. DeVries, Dong Cheng, Jonathan A. Meulbroek, Fritz G. Buchanan, Laura M. McKay, Neal Goodwin, Edward B. Reilly	2016	136
7	Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models Molecular Cancer Therapeutics ·Elizabeth A. Punnoose, Joel Johansson, Franklin Peale, Erwin R. Boghaert, Lisa D. Belmont, Nguyen Tan, A. Young, Michael J. Mitten, Ellen Ingalla, Walter C. Darbonne, Anatol Oleksijew, Paul Tapang, Yue Peng, Jason Oeh, Leslie Lee, Sophie Maïga, Wayne J. Fairbrother, Martine Amiot, Andrew J. Souers, Deepak Sampath	2016	223
8	Hit to Lead optimization of a novel class of squarate-containing polo-like kinases inhibitors Bioorganic & Medicinal Chemistry Letters ·Qingwei Zhang, admin pTools, Michael J. Mitten, Loren Lasko, Vered Klinghofer, Jennifer J. Bouska, Eric F. Johnson, Thomas D. Penning, Yan Luo, Vincent L. Giranda, Alexander R. Shoemaker, Kent D. Stewart, Stevan W. Djurić, Anil Vasudevan	2012	12
9	The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo Molecular Cancer Therapeutics ·Jun Chen, Sha Jin, Myriam Steinback, Xiaoli Huang, Bernard A. Liu, Michael J. Mitten, Paul Nimmer, Xiaoyu Lin, Morey L. Smith, Yu Shen, Alexander R. Shoemaker, Stephen K. Tahir, Haichao Zhang, Scott Ackler, Saul H. Rosenberg, Heather Maecker, Deepak Sampath, Joel Johansson, Chris Tse, Steven W. Elmore	2011	119
10	The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo Cancer Chemotherapy and Pharmacology ·Scott Ackler, Michael J. Mitten, Kelly Foster, Anatol Oleksijew, Marion Refici, Stephen K. Tahir, Xiao Yu, Christin Tse, David J. Frost, Stephen W. Fesik, Saul H. Rosenberg, Steven W. Elmore, Alexander R. Shoemaker	2010	100
11	ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor Cancer Research ·Christin Tse, Alexander R. Shoemaker, Jessica Adickes, Mark G. Anderson, Jun Chen, Sha Jin, Eric F. Johnson, Kennan C. Marsh, Michael J. Mitten, Paul Nimmer, Lisa Roberts, Stephen K. Tahir, Xiao Yu, Xiufen Yang, Haichao Zhang, Stephen W. Fesik, Saul H. Rosenberg, Steven W. Elmore Hit paper breakdown →	2008	1513
12	ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo Molecular Cancer Therapeutics ·Scott Ackler, Xiao Yu, Michael J. Mitten, Kelly Foster, Anatol Oleksijew, Marion Refici, Analizza Ina Lea, Baole Wang, Sanjay R. Chemburkar, Joy Bauch, Christin Tse, David J. Frost, Stephen W. Fesik, Saul H. Rosenberg, Steven W. Elmore, Alex R. Shoemaker	2008	64
13	Practical Preclinical Model for Assessing the Potential for Unconjugated Hyperbilirubinemia Produced by Human Immunodeficiency Virus Protease Inhibitors Antimicrobial Agents and Chemotherapy ·Dale J. Kempf, Jeffrey F. Waring, David C. Morfitt, Kuan-wu Lin, DuckChaeJung, Michael J. Mitten, Bach Nguyen, John T. Randolph, David A. DeGoey, Larry L. Klein, Kennan C. Marsh	2006	6
14	Synthesis and antibacterial activity of 6-O-arylpropargyl-9-oxime-11,12-carbamate ketolides Bioorganic & Medicinal Chemistry Letters ·Xenia Beebe, Fan Yang, Mai H. Bui, Michael J. Mitten, Zhenkun Ma, Angela M. Nilius, Stevan W. Djurić	2004	16
15	Sialylation of Lipooligosaccharides Promotes Biofilm Formation by Nontypeable Haemophilus influenzae Infection and Immunity ·W. Edward Swords, Endre Prakfalvi, Alan N. Lau, Gail Bukofzer, Michael J. Mitten, Jessica L. VonCannon	2003	115
16	Design, Synthesis, and Antimicrobial Activity of 6-O-Substituted Ketolides Active against Resistant Respiratory Tract Pathogens Journal of Medicinal Chemistry ·Yat Sun Or, Richard F. Clark, Sanyi Wang, Daniel T. W. Chu, Angela M. Nilius, Robert K. Flamm, Michael J. Mitten, Patty J. Ewing, Jeff Alder, Zhenkun Ma	2000	87
17	Model of Streptococcus pneumoniae meningitis in adult rats. PubMed ·Joko Hadi Purwanto, Michael J. Mitten, 文雄鈴村, J. D. Alder	1996	4
18	Efficacies of ABT-719 and related 2-pyridones, members of a new class of antibacterial agents, against experimental bacterial infections Antimicrobial Agents and Chemotherapy ·Jeff Alder, Jacob J. Clement, Jonathan A. Meulbroek, N. L. Shipkowitz, Michael J. Mitten, 関根詮明, Anatol Oleksijew, Lada TANCEROVÁ, Al-Amin Abdulhamid, L. N. Karmazina	1995	15
19	Treatment of experimental Pneumocystis carinii infection by combination of clarithromycin and sulphamethoxazole Journal of Antimicrobial Chemotherapy ·Jeffrey Alder, Michael J. Mitten, Diego Javier Musacchio, Lisa E. Hernandez, Yu‐Hua Hui, Kennan C. Marsh, Jacob J. Clement	1994	8
20	Efficacy of A-73209, a potent orally active agent against VZV and HSV infections Antiviral Research ·Jeffrey Alder, Michael J. Mitten, R. W. Putnam, Kennan C. Marsh, G. Bozzini, Jacob J. Clement	1994	16

About Michael J. Mitten

Michael J. Mitten is a scholar working on Microbiology, Hematology, Molecular Medicine, Oncology and Epidemiology, having authored 27 papers that have together received 2.8k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (6 papers), Pneumonia and Respiratory Infections (5 papers), Multiple Myeloma Research and Treatments (4 papers), Monoclonal and Polyclonal Antibodies Research (4 papers), Pneumocystis jirovecii pneumonia detection and treatment (3 papers), Cell death mechanisms and regulation (3 papers), Cancer-related Molecular Pathways (3 papers) and Bacterial Infections and Vaccines (3 papers). The work is most often cited by research in Genetics (352 citations), Hematology (358 citations), Oncology (832 citations), Molecular Biology (1.9k citations) and Microbiology (102 citations). Michael J. Mitten has collaborated with scholars based in United States, Australia and Portugal. Frequent co-authors include Saul H. Rosenberg, Steven W. Elmore, Christin Tse, Stephen W. Fesik, Stephen K. Tahir, Alexander R. Shoemaker, Kennan C. Marsh, Xiao Yu, Xiufen Yang and Jessica Adickes. Their work appears in journals such as Molecular Cancer Therapeutics, Antimicrobial Agents and Chemotherapy, Bioorganic & Medicinal Chemistry Letters, Journal of Medicinal Chemistry and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact